252 related articles for article (PubMed ID: 26397968)
41. Efficacy and tolerability of local estrogen therapy for urogenital atrophy.
Archer DF
Menopause; 2010; 17(1):194-203. PubMed ID: 19602990
[TBL] [Abstract][Full Text] [Related]
42. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society.
Portman DJ; Gass ML;
Maturitas; 2014 Nov; 79(3):349-54. PubMed ID: 25179577
[TBL] [Abstract][Full Text] [Related]
43. [Current aspects of the treatment of urogenital atrophy (based on the consensus of britain society of menopause)].
Balan VE; Tikhomirova EV; Tsarkova AV; Gadgieva ZK
Urologiia; 2019 Dec; (5):150-154. PubMed ID: 31808652
[TBL] [Abstract][Full Text] [Related]
44. Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women.
Simon JA; Reape KZ; Wininger S; Hait H
Fertil Steril; 2008 Oct; 90(4):1132-8. PubMed ID: 18053998
[TBL] [Abstract][Full Text] [Related]
45. Ospemifene, vulvovaginal atrophy, and breast cancer.
Wurz GT; Soe LH; DeGregorio MW
Maturitas; 2013 Mar; 74(3):220-5. PubMed ID: 23332519
[TBL] [Abstract][Full Text] [Related]
46. Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner.
Labrie F; Montesino M; Archer DF; Lavoie L; Beauregard A; Côté I; Martel C; Vaillancourt M; Balser J; Moyneur E;
Climacteric; 2015; 18(6):817-25. PubMed ID: 26517756
[TBL] [Abstract][Full Text] [Related]
47. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.
Kagan R; Williams RS; Pan K; Mirkin S; Pickar JH
Menopause; 2010 Mar; 17(2):281-9. PubMed ID: 19779382
[TBL] [Abstract][Full Text] [Related]
48. Ospemifene in the treatment of vulvovaginal atrophy.
Barnes KN; Pearce EF; Yancey AM; Forinash AB
Ann Pharmacother; 2014 Jun; 48(6):752-7. PubMed ID: 24615631
[TBL] [Abstract][Full Text] [Related]
49. Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide.
Hirschberg AL; Bitzer J; Cano A; Ceausu I; Chedraui P; Durmusoglu F; Erkkola R; Goulis DG; Kiesel L; Lopes P; Pines A; van Trotsenburg M; Lambrinoudaki I; Rees M
Maturitas; 2021 Jun; 148():55-61. PubMed ID: 33896654
[TBL] [Abstract][Full Text] [Related]
50. Vulvar and vaginal atrophy as viewed by the Spanish REVIVE participants: symptoms, management and treatment perceptions.
Palacios S; Cancelo MJ; Castelo Branco C; Llaneza P; Molero F; Borrego RS
Climacteric; 2017 Feb; 20(1):55-61. PubMed ID: 28042734
[TBL] [Abstract][Full Text] [Related]
51. What's new in the world of postmenopausal sex?
Iglesia CB
Curr Opin Obstet Gynecol; 2016 Oct; 28(5):449-54. PubMed ID: 27517339
[TBL] [Abstract][Full Text] [Related]
52. Prasterone: A Review in Vulvovaginal Atrophy.
Heo YA
Drugs Aging; 2019 Aug; 36(8):781-788. PubMed ID: 31290076
[TBL] [Abstract][Full Text] [Related]
53. Prevalence and impact of vaginal symptoms among postmenopausal women.
Santoro N; Komi J
J Sex Med; 2009 Aug; 6(8):2133-42. PubMed ID: 19493278
[TBL] [Abstract][Full Text] [Related]
54. Treatment of postmenopausal vaginal atrophy with 10-μg estradiol vaginal tablets.
Panay N; Maamari R
Menopause Int; 2012 Mar; 18(1):15-9. PubMed ID: 22393176
[TBL] [Abstract][Full Text] [Related]
55. What happened to WHI: menopausal hormonal therapy in 2012.
Hansen KA; Eyster KM
Clin Obstet Gynecol; 2012 Sep; 55(3):706-12. PubMed ID: 22828102
[TBL] [Abstract][Full Text] [Related]
56. The Women's EMPOWER Survey: Identifying Women's Perceptions on Vulvar and Vaginal Atrophy and Its Treatment.
Kingsberg SA; Krychman M; Graham S; Bernick B; Mirkin S
J Sex Med; 2017 Mar; 14(3):413-424. PubMed ID: 28202320
[TBL] [Abstract][Full Text] [Related]
57. Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors.
Pieralli A; Fallani MG; Becorpi A; Bianchi C; Corioni S; Longinotti M; Tredici Z; Guaschino S
Arch Gynecol Obstet; 2016 Oct; 294(4):841-6. PubMed ID: 27170261
[TBL] [Abstract][Full Text] [Related]
58. Genitourinary Syndrome of Menopause.
Shifren JL
Clin Obstet Gynecol; 2018 Sep; 61(3):508-516. PubMed ID: 29787390
[TBL] [Abstract][Full Text] [Related]
59. Characteristics of post-menopausal women with genitourinary syndrome of menopause: Implications for vulvovaginal atrophy diagnosis and treatment selection.
Castelo-Branco C; Biglia N; Nappi RE; Schwenkhagen A; Palacios S
Maturitas; 2015 Aug; 81(4):462-9. PubMed ID: 26071816
[TBL] [Abstract][Full Text] [Related]
60. BMS - Consensus statement.
Pitkin J;
Post Reprod Health; 2018 Sep; 24(3):133-138. PubMed ID: 30244644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
